Novo Nordisk A/S – Total number of voting rights and share capital in Novo Nordisk A/S as of 26 April 2024
26 avr. 2024 06h16 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 26 April 2024 – In accordance with Section 32 of the Danish Capital Markets Act, Novo Nordisk A/S is required to publish the total number of voting rights and the size of the share...
Gennemførelse af kapitalnedsættelse i Spar Nord Bank A/S
26 avr. 2024 02h45 HE
|
Spar Nord Bank A/S
Selskabsmeddelelse nr. 28 Som oplyst i selskabsmeddelelse nr. 22 blev det på Spar Nord Bank A/S’ ordinære generalforsamling den 19. marts 2024 besluttet at nedsætte selskabets...
Completion of capital reduction in Spar Nord Bank A/S
26 avr. 2024 02h45 HE
|
Spar Nord Bank A/S
Company announcement no. 28 As stated in company announcement no. 22, it was decided at Spar Nord Bank A/S’ ordinary general meeting on 19 March 2024 to reduce the company’s share...
Equinor ASA: Nøkkelinformasjon ved kontantutbytte for første kvartal 2024
25 avr. 2024 00h46 HE
|
Equinor ASA
Nøkkelinformasjon ved kontantutbytte for Equinor (OSE: EQNR, NYSE: EQNR) for første kvartal 2024. Ordinært utbyttebeløp: 0,35 Ekstraordinært utbyttebeløp: 0,35 Annonsert valuta: USD Siste dag...
Equinor ASA: Key information relating to cash dividend for first quarter 2024
25 avr. 2024 00h46 HE
|
Equinor ASA
Key information relating to the cash dividend to be paid by Equinor (OSE: EQNR, NYSE: EQNR) for first quarter 2024. Ordinary cash dividend amount: 0.35 Extraordinary cash dividend amount: 0.35 ...
Ensurge Micropower ASA - Grant of Incentive Subscription Rights
24 avr. 2024 17h30 HE
|
Ensurge Micropower ASA
The Board of Directors of Ensurge Micropower ASA (the "Company") resolved on 24 April 2024 to issue a total of 202,200 incentive subscription rights to employees in the Ensurge group. The grants were...
TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares
24 avr. 2024 11h03 HE
|
TScan Therapeutics, Inc.
WALTHAM, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered...
Fly Play hf.: Hækkun hlutafjár
24 avr. 2024 10h16 HE
|
FLYPLAY HF
Vísað er til tilkynningu Fly Play hf. („PLAY“ eða „félagið“) frá 11. apríl 2024 um niðurstöður úr fjármögnunarlotu. Á fundi sínum í dag ákvað stjórn PLAY að nýta heimild þá sem aðalfundur veitti til...
Fly Play hf.: Increase of share capital
24 avr. 2024 10h16 HE
|
FLYPLAY HF
Reference is made to the announcement of Fly Play hf. (“PLAY” or the “Company”) on April 11, 2024, regarding the results of a funding round. In a meeting held today, the Company’s Board of Directors...
Novo Nordisk A/S – Reduction of the share capital
24 avr. 2024 08h48 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 24 April 2024 – At Novo Nordisk’s Annual General Meeting on 21 March 2024, it was decided to reduce the company’s B share capital from DKK 343,512,800 to DKK 339,012,800 by...